Lemoine H, Worth H, Reinhardt D
Biomedizinisches Forschungszentrum, Heinrich-Heine-Universität, Düsseldorf.
Pneumologie. 1993 Apr;47(4):303-10.
In severe asthma attacks, beta 2-sympathomimetics can lose part of their therapeutic potency possibly due to a predominance of contractile mediators. To elucidate this loss of potency, we chose tracheal smooth muscle strips as experimental model which were partially and maximally precontracted with 100 and 6,000 nmol/l carbachol, respectively, reflecting different contractile states of the smooth muscle strips. Both contractures were dose-dependently relaxed by fenoterol and salbutamol which are well established as beta 2-sympathomimetics, by a new compound (formoterol) and by isoprenaline as standard. In tracheal strips, partially precontracted with 100 nmol/l carbachol, all agonists induced maximum relaxation beyond basal tone thereby characterized as full agonists. In maximally precontracted tracheal strips beta-adrenergic relaxation was markedly attenuated for all agonists by 70-80%. Maximum relaxation by the beta 2-sympathomimetics was even smaller than that of isoprenaline. By these experiments, the beta 2-sympathomimetics were characterized as partial agonists. The intrinsic 'activities (IA) for relaxation were different for the 3 beta 2-sympathomimetics investigated. Intrinsic activities were 0.8, 0.6 and 0.6 for formoterol, fenoterol and salbutamol, respectively. In both group of experiments formoterol exhibited the lowest EC50 for relaxation, which was 20 and 50 times lower than that of fenoterol and salbutamol, respectively. To investigate, if the higher relaxant potency of formoterol correlated to a higher binding affinity for beta 2-adrenoceptors, we performed radioligand binding experiments in guinea pig lung membranes. The non-linear regression analysis of data revealed a high affinity of formoterol, which was 16- and 40-fold higher than that of fenoterol and salbutamol, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
在严重哮喘发作时,β2 肾上腺素能激动剂可能会失去部分治疗效力,这可能是由于收缩介质占主导地位所致。为了阐明这种效力丧失的原因,我们选择气管平滑肌条作为实验模型,分别用 100 和 6000 nmol/l 的卡巴胆碱使其部分和最大程度预收缩,以反映平滑肌条的不同收缩状态。两种收缩状态均呈剂量依赖性地被非诺特罗、沙丁胺醇(已被确认为β2 肾上腺素能激动剂)、一种新化合物(福莫特罗)和作为标准的异丙肾上腺素松弛。在 100 nmol/l 卡巴胆碱部分预收缩的气管条中,所有激动剂均诱导出超过基础张力的最大松弛,因此被表征为完全激动剂。在最大程度预收缩的气管条中,所有激动剂的β肾上腺素能松弛均显著减弱 70 - 80%。β2 肾上腺素能激动剂的最大松弛甚至比异丙肾上腺素还要小。通过这些实验,β2 肾上腺素能激动剂被表征为部分激动剂。所研究的 3 种β2 肾上腺素能激动剂的内在“活性”(IA)用于松弛作用时各不相同。福莫特罗、非诺特罗和沙丁胺醇的内在活性分别为 0.8、0.6 和 0.6。在两组实验中,福莫特罗的松弛作用 EC50 最低,分别比非诺特罗和沙丁胺醇低 20 倍和 50 倍。为了研究福莫特罗较高的松弛效力是否与其对β2 肾上腺素能受体的较高结合亲和力相关,我们在豚鼠肺膜上进行了放射性配体结合实验。数据的非线性回归分析显示福莫特罗具有高亲和力,分别比非诺特罗和沙丁胺醇高 16 倍和 40 倍。(摘要截选至 250 字)